US$ 20.28
bryan johnson ghk cu How one entrepreneur is tackling humanity's most pressing problems Biohacker Bryan Johnson didn’t just
Description
2009b;381:4955
Med Clin Exp 2004;27:10-3

What the research firmly supports: BPC-157's gut healing, vascular, and neuroprotective mechanisms (strong preclinical evidence) Thymosin Alpha-1's immune modulating and T-cell restorative effects (strong preclinical + clinical evidence in viral disease) TB-500's cardiovascular repair and angiogenic properties (strong preclinical, early human data) What the research does not yet confirm: Randomised controlled trial data specifically in long COVID populations Optimal dosing, sequencing, and duration specifically for PASC Long-term safety data for extended post-viral use This doesn't mean these peptides don't work for long COVID

Shuqiang et al